Irodalom 1 Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. American Journal of Clinical Pathology 2004
References 1 Nagy Zs. Multiple myeloma and other plasma cell dyscrasias. [Mielóma multiplex és egyéb plazmasejtes diszkráziák.] Magy Onkol. 2016; 60
, Bross PF , Farrell AT , Pazdur R : Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy . The Oncologist 8 , 508 – 513 ( 2003 ) 2
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15: e538– e548. 11
2): 24–25. 5 Marchesi F, Pimpinelli F, Gumenyuk S, et al. Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: a single
myeloma kidney injury. Blood 107 , 661–668. Batuman V. Potential protective action of pituitary adenylate cyclase activating polypeptide (PACAP38) on in vitro and in vivo models of
Rosen, L. S., Gordon, D., Kaminski, M., et al.: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized
with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol. Dial. Transplant., 2010, 25 , 419–426. Collins G. P. Presentation and
. J Infect Dis. 1987; 156: 471–477. 18 Teh BW, Harrison SJ, Worth LJ, et al. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort
Biszfoszfonát-kezelés során fellépő állcsontnecrosis
Gyakorlati útmutató a biszfoszfonáttal kezelt betegeknél fellépő osteonecrosis megelőzéséhez és kezeléséhez
jaws in myeloma: Time dependent correlation with Aredia and Zometa use Blood 104 216a abstr 756. 6. KL Gebhard